Diagnostyka

Diagnostyka EBIT per Share

The EBIT per Share of Diagnostyka (DIA.WA) as of Oct 27, 2026 is 11.37 PLN. In the previous year, EBIT per Share was 9.99 PLN — a change of 13.76% (higher).

EBIT per Share

11.37PLN

YoY

13.76%

Last updated:

EBIT per Share of Diagnostyka is 2025 11.37 PLN. EBIT per Share of Diagnostyka was 2024 9.99 PLN. It decreases by 13.76% higher compared to the previous year.

The Diagnostyka EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2024
9.99 PLN
Jan 1, 2025
11.37 PLN
Jan 1, 2026 (e)
15.04 PLN
Jan 1, 2027 (e)
17.35 PLN
Jan 1, 2028 (e)
20.04 PLN
Jan 1, 2029 (e)
21.17 PLN
Jan 1, 2030 (e)
22.58 PLN
Jan 1, 2031 (e)
0.00 PLN
The Diagnostyka EBIT per Share history
YEAREBIT per ShareYoY
est0.00PLN-100.00%
est22.58PLN+6.64%
est21.17PLN+5.67%
est20.04PLN+15.46%
est17.35PLN+15.34%
est15.04PLN+32.37%
11.37PLN+13.76%
9.99PLN+44.48%
6.92PLN-7.39%
7.47PLN-63.34%
20.37PLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Diagnostyka Stock analysis

What does Diagnostyka do? Diagnostyka SA generates revenue through its network of 180 laboratories and 1,100 Sampling Labs across Poland, offering over 3,000 test types including hematology, infection diagnostics, allergology, and hormonal diagnostics. The company provides both routine and specialist laboratory services, with tests available with or without a physician's referral, catering to individual patients and healthcare providers. Its specialization in molecular biology, autoimmune diagnostics, and blood collection drives demand from private individuals seeking direct access to medical analysis without a doctor's prescription. The firm's revenue model relies on a comprehensive service chain from biological material collection and transportation to final analysis results, serving a broad customer base including patients, clinics, and hospitals. With a focus on accessible diagnostics, Diagnostyka SA expands its market reach through its extensive lab network, enabling widespread availability of medical testing services throughout Poland. The company's ability to deliver specialized tests like molecular biology and autoimmune diagnostics differentiates its offerings in the healthcare sector. Diagnostyka is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Diagnostyka stock

EBIT per Share of Diagnostyka is 11.37 PLN in 2025.

EBIT per Share of Diagnostyka changed from 9.99 PLN to 11.37 PLN, representing a 13.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Diagnostyka since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Diagnostyka

All Key Metrics — Diagnostyka